Glenview Trust Co Has $23.53 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

by · The Cerbat Gem

Glenview Trust Co lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 14.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 34,787 shares of the company’s stock after selling 5,942 shares during the quarter. Glenview Trust Co’s holdings in IDEXX Laboratories were worth $23,534,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. New Age Alpha Advisors LLC lifted its stake in shares of IDEXX Laboratories by 1.5% during the 4th quarter. New Age Alpha Advisors LLC now owns 4,127 shares of the company’s stock worth $2,792,000 after buying an additional 61 shares during the last quarter. Simplify Asset Management Inc. lifted its stake in shares of IDEXX Laboratories by 21.7% during the 4th quarter. Simplify Asset Management Inc. now owns 584 shares of the company’s stock worth $395,000 after buying an additional 104 shares during the last quarter. Swedbank AB lifted its stake in shares of IDEXX Laboratories by 0.3% during the 4th quarter. Swedbank AB now owns 37,962 shares of the company’s stock worth $25,682,000 after buying an additional 130 shares during the last quarter. Prospera Financial Services Inc acquired a new stake in IDEXX Laboratories in the 4th quarter worth about $4,188,000. Finally, Coldstream Capital Management Inc. raised its stake in IDEXX Laboratories by 8.4% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,893 shares of the company’s stock worth $1,281,000 after purchasing an additional 146 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $559.37 on Monday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $496.61 and a twelve month high of $769.98. The stock has a market capitalization of $44.12 billion, a price-to-earnings ratio of 41.19, a price-to-earnings-growth ratio of 3.25 and a beta of 1.58. The company has a 50-day simple moving average of $566.51 and a two-hundred day simple moving average of $642.13.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the firm earned $2.91 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Insider Activity

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 2,693 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $661.54, for a total value of $1,781,527.22. Following the transaction, the executive vice president directly owned 19,899 shares of the company’s stock, valued at $13,163,984.46. This trade represents a 11.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 27,777 shares of company stock worth $18,235,113. Insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of several analyst reports. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Barclays dropped their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

Read Our Latest Research Report on IDEXX Laboratories

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Featured Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).